Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Vitamin D Deficiency, Insulin Resistance and FGF-23

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00491322
Recruitment Status : Completed
First Posted : June 26, 2007
Results First Posted : May 2, 2018
Last Update Posted : May 2, 2018
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Sherri-Ann M. Burnett-Bowie, Massachusetts General Hospital

Brief Summary:
The purpose of this project is to determine if treating vitamin D deficiency decreases insulin resistance and improves insulin secretion in healthy volunteers. Additionally, this project will investigate if treating vitamin D deficiency affects a new phosphate-regulating hormone called FGF-23.

Condition or disease Intervention/treatment Phase
Vitamin D Deficiency Dietary Supplement: Ergocalciferol Dietary Supplement: Ergocalciferol placebo Not Applicable

Detailed Description:

Vitamin D deficiency or hypovitaminosis D, defined as serum 25 hydroxyvitamin D < or = 20 ng/mL, is prevalent in several populations in the United States, specifically minorities and the elderly. Causes of vitamin D deficiency include lack of exposure to sunlight, malnutrition, and drugs that alter vitamin D metabolism and absorption.

Vitamin D is an essential factor for many organ systems. Data suggest that vitamin D is required for normal insulin secretion by the pancreas. Specifically, animal studies demonstrate that treatment of vitamin D deficiency improves insulin secretion. In humans, there is less consensus about the impact of vitamin D deficiency on insulin resistance. In one study of middle-aged patients with Type 2 diabetes mellitus, no association was seen between serum 25 hydroxyvitamin D levels and a measure of insulin resistance. However, in a larger study of younger glucose tolerant subjects, serum 25 hydroxyvitamin D levels were associated with both insulin secretion and insulin resistance. These data suggest that treatment of vitamin D deficiency may delay or prevent the development of insulin resistance, and thus diabetes mellitus type 2. Repletion of this common vitamin deficiency could therefore have major public health implications for the prevention of diabetes mellitus.

Fibroblast growth factor 23 (FGF-23) is a newly discovered phosphaturic hormone that is regulated by both dietary and serum phosphate. Hormonal regulation of FGF-23, however, is largely unknown. Recent data suggest that vitamin D plays an important role in the regulation of FGF-23. Some groups have shown that inactivation of the vitamin D receptor gene decreases serum FGF-23 levels in mice; administration of 1,25 dihydroxyvitamin D stimulates the transcription of the FGF-23 gene in vitro. Little is known, however, about the regulation of FGF-23 by vitamin D in humans.

Phosphate is critical for bone mineralization, muscle function, signal transduction, and the creation and utilization of energy. Vitamin D deficiency can result in phosphate malabsorption, osteomalacia and increased risk of fractures. Enhanced understanding of the regulation of this new phosphate-regulating hormone, FGF-23, will advance the field of phosphate metabolism.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 92 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Impact of Vitamin D Deficiency on Insulin Resistance and the Regulation of FGF-23
Study Start Date : May 2006
Actual Primary Completion Date : February 2008
Actual Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Ergocalciferol group
Ergocalciferol 50000 international units once a week for 12 weeks
Dietary Supplement: Ergocalciferol
Ergocalciferol 50000 international units once a week for 12 weeks

Placebo Comparator: Ergocalciferol Placebo group
Matching placebo once a week for 12 weeks
Dietary Supplement: Ergocalciferol placebo
Ergocalciferol placebo once a week for 12 weeks

Primary Outcome Measures :
  1. Fibroblast Growth Factor 23 (FGF23) After 12 Weeks of Weekly Ergocalciferol 50000 Units [ Time Frame: 12 weeks ]
    Fibroblast growth factor 23 (FGF23) is a phosphate and vitamin D regulating hormone.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18 to 45 yrs
  • Serum 25-OHD < or = 20 ng/mL
  • At least 1 menses in the last 3 months (females) and normal serum testosterone (males)

Exclusion Criteria:

  • Significant cardiac, hepatic, oncologic, or psychiatric disease
  • History of diabetes mellitus, malabsorption, kidney stones, or recent alcohol excess/abuse (15 drinks per week in the last month)
  • Fasting glucose > 126 mg/dl or 2 hour OGTT > 200 mg/dl
  • Use of medications known to affect serum phosphate levels including phosphate-binding antacids, sodium etidronate, calcitonin, excessive doses of vitamin D (> 1000 units per day), excessive doses of vitamin A (> 20,000 units/day), calcitriol, growth hormone, or anti-convulsants
  • Use of metformin or insulin sensitizing agents
  • Serum calcium < 8 or > 11 mg/dL, creatinine > 1.5 mg/dL, or Hgb < 11 gm/dL
  • Liver function tests > 2 times the upper limit of normal
  • TSH < 0.1 or > 7 uU/mL
  • WBC < 2,000 or > 15,000/cmm
  • Platelet count < 100,000 or > 500,000/cum
  • Hormone replacement therapy or testosterone use
  • Urine uhCG positive (females), testosterone < 270 ng/dL (males)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00491322

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Layout table for investigator information
Principal Investigator: Sherri-Ann M Burnett-Bowie, MD, MPH Massachusetts General Hospital
Publications of Results:
Other Publications:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sherri-Ann M. Burnett-Bowie, Assistant Professor of Medicine, Massachusetts General Hospital Identifier: NCT00491322    
Other Study ID Numbers: 2006-P-000430/18
K23DK073356 ( U.S. NIH Grant/Contract )
First Posted: June 26, 2007    Key Record Dates
Results First Posted: May 2, 2018
Last Update Posted: May 2, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sherri-Ann M. Burnett-Bowie, Massachusetts General Hospital:
Vitamin D
Vitamin D deficiency
Insulin resistance
Diabetes mellitus
Additional relevant MeSH terms:
Layout table for MeSH terms
Insulin Resistance
Vitamin D Deficiency
Glucose Metabolism Disorders
Metabolic Diseases
Deficiency Diseases
Nutrition Disorders
Vitamin D
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents